

Darren M Riddy

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7431626/publications.pdf>

Version: 2024-02-01

14
papers

466
citations

759055

12
h-index

996849

15
g-index

16
all docs

16
docs citations

16
times ranked

876
citing authors

#	ARTICLE	IF	CITATIONS
1	Multipathway In Vitro Pharmacological Characterization of Specialized Proresolving G Protein-Coupled Receptors. <i>Molecular Pharmacology</i> , 2022, 101, 246-256.	1.0	7
2	Deletion of GPR21 improves glucose homeostasis and inhibits the CCL2-CCR2 axis by divergent mechanisms. <i>BMJ Open Diabetes Research and Care</i> , 2021, 9, e002285.	1.2	6
3	Acetylcholine Muscarinic M4 Receptors as a Therapeutic Target for Alcohol Use Disorder: Converging Evidence From Humans and Rodents. <i>Biological Psychiatry</i> , 2020, 88, 898-909.	0.7	24
4	New Advances in Targeting the Resolution of Inflammation: Implications for Specialized Pro-Resolving Mediator GPCR Drug Discovery. <i>ACS Pharmacology and Translational Science</i> , 2020, 3, 88-106.	2.5	80
5	Drug-receptor kinetics and sigma-1 receptor affinity differentiate clinically evaluated histamine H3 receptor antagonists. <i>Neuropharmacology</i> , 2019, 144, 244-255.	2.0	22
6	G Protein-Coupled Receptors Targeting Insulin Resistance, Obesity, and Type 2 Diabetes Mellitus. <i>Pharmacological Reviews</i> , 2018, 70, 39-67.	7.1	88
7	Comparative genotypic and phenotypic analysis of human peripheral blood monocytes and surrogate monocyte-like cell lines commonly used in metabolic disease research. <i>PLoS ONE</i> , 2018, 13, e0197177.	1.1	29
8	Isoform-Specific Biased Agonism of Histamine H ₃ Receptor Agonists. <i>Molecular Pharmacology</i> , 2017, 91, 87-99.	1.0	21
9	Discovery of Fevipiprant (NVP-QAW039), a Potent and Selective DP ₂ Receptor Antagonist for Treatment of Asthma. <i>ACS Medicinal Chemistry Letters</i> , 2017, 8, 582-586.	1.3	30
10	Fevipiprant (QAW039), a Slowly Dissociating CRTh2 Antagonist with the Potential for Improved Clinical Efficacy. <i>Molecular Pharmacology</i> , 2016, 89, 593-605.	1.0	56
11	Label-Free Kinetics: Exploiting Functional Hemi-Equilibrium to Derive Rate Constants for Muscarinic Receptor Antagonists. <i>Molecular Pharmacology</i> , 2015, 88, 779-790.	1.0	17
12	Investigating the molecular mechanisms through which <i>FTY720</i> causes persistent S1P ₁ receptor internalization. <i>British Journal of Pharmacology</i> , 2014, 171, 4797-4807.	2.7	46
13	Reassessment of the pharmacology of Sphingosine-1-phosphate S1P ₃ receptor ligands using the DiscoverX PathHunter [®] and Ca ²⁺ release functional assays. <i>British Journal of Pharmacology</i> , 2012, 167, 868-880.	2.7	13
14	A prospective study of isolated human hepatocyte function following liver resection for colorectal liver metastases: The effects of prior exposure to chemotherapy. <i>Journal of Hepatology</i> , 2006, 45, 263-270.	1.8	26